logo
  

Innate Pharma: Avdoralimab Phase 2 FORCE Trial In COVID-19 With Pneumonia Did Not Meet Primary Goals

Innate Pharma SA (IPHA) announced Tuesday that the investigator-sponsored Avdoralimab Phase 2 FORCE Trial in COVID-19 Patients with severe pneumonia did not meet primary endpoints in all three cohorts of the trial.

Based on these results, the company will stop exploring avdoralimab in COVID-19.

Meanwhile, the company will continue its investigator-sponsored Phase 2 trial of avdoralimab in bullous pemphigoid, an inflammatory disease, which is currently enrolling patients. More than 100 patients have been treated with avdoralimab in inflammation and oncology clinical trials with no new or unexpected safety signals observed.

The company noted that the Phase 2 FORCE (FOR COVID-19 Elimination) clinical trial evaluated the safety and efficacy of its anti-C5aR1 antibody, avdoralimab, in COVID-19 patients with severe pneumonia.

The FORCE trial was initiated based on pre-clinical data showing that patients who progress towards severe COVID-19 disease exhibit an activation of the C5a/C5aR1 pathway. These translational data were observed in the trial; however, they did not translate into clinical benefit over best supportive care.

According to the company, investigators and the Independent Data Monitoring Committee observed slightly higher deaths in the treatment arm compared to placebo without causality being established.

Results from this trial, including translational data, are planned to be submitted for publication.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Cryptocurrency Dogecoin's price jumped over 15% on Friday, but later lost some of the gains, after Tesla Inc. (TSLA) CEO Elon Musk announced that the luxury car maker will start accepting the meme cryptocurrency as payment for its merchandise. "Tesla merch buyable with Dogecoin," Musk tweeted on Friday. Dogecoin... US investment bank JPMorgan Chase & Co. reported Friday a profit for the fourth quarter that declined 14 percent from last year, hurt primarily by higher noninterest expense and lower credit reserve releases. Both adjusted earnings per share and revenues for the quarter topped analysts' expectations. Microsoft Corp. said its Board of Directors has initiated a review of the effectiveness of its workplace sexual harassment and gender discrimination policies and practices. The company has hired the law firm of Arent Fox to conduct the review mainly on sexual harassment investigations, including that of co-founder Bill Gates.
RELATED NEWS
Follow RTT